Patents by Inventor Daniel Shore

Daniel Shore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators
    Patent number: 11236046
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: February 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Yanyan Chu, Steven Do, Anthony Estrada, Baihua Hu, Aleksandr Kolesnikov, Xingyu Lin, Joseph P. Lyssikatos, Daniel Shore, Vishal Verma, Lan Wang, Guosheng Wu, Po-wai Yuen
  • Biheteroaryl compounds and uses thereof
    Patent number: 11129832
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: September 28, 2021
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph P. Lyssikatos, Alan G. Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • Oxadiazolones as transient receptor potential channel inhibitors
    Patent number: 10913742
    Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: February 9, 2021
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Daniel Shore, Elisia Villemure, Matthew Volgraf, Baihua Hu, Aijun Lu, Andrew Cridland, Stuart Ward, Francis Beaumier, Martin Dery, Robin Larouche-Gauthier
  • Oxadiazole transient receptor potential channel inhibitors
    Patent number: 10711004
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: July 14, 2020
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Brian Safina, Daniel Shore, Jack Terrett, Elisia Villemure, Matthew Volgraf, Stuart Ward, Aijun Lu, Robin Larouche-Gauthier, Francis Beaumier, Martin Dery, Lea Constantineau-Forget, Chantal Grand-Maitre, Luce Lepissier
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20200188397
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Application
    Filed: October 28, 2019
    Publication date: June 18, 2020
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph Lyssikatos, Alan Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • Bicyclic proline compounds
    Patent number: 10597383
    Abstract: The invention is concerned with the compounds of formula I: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: March 24, 2020
    Assignee: Genentech, Inc.
    Inventors: Vishal Verma, Daniel Shore, Matthew Volgraf, Anthony A. Estrada, Joseph Lyssikatos
  • SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
    Publication number: 20200048197
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 13, 2020
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Yanyan CHU, Steven DO, Anthony ESTRADA, Baihua HU, Aleksandr KOLESNIKOV, Xingyu LIN, Joseph P. LYSSIKATOS, Daniel SHORE, Vishal VERMA, Lan WANG, Guosheng WU, Po-wai YUEN
  • OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20200002340
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: September 3, 2019
    Publication date: January 2, 2020
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Brian SAFINA, Daniel SHORE, Jack TERRETT, Elisia VILLEMURE, Matthew VOLGRAF, Stuart WARD, Aijun LU, Robin LAROUCHE-GAUTHIER, Francis BEAUMIER, Martin DERY, Lea CONSTANTINEAU-FORGET, Chantal GRAND-MAITRE, Luce LEPISSIER
  • OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
    Publication number: 20190284189
    Abstract: The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 19, 2019
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Daniel SHORE, Elisia VILLEMURE, Matthew VOLGRAF, Baihua HU, Aijun LU, Andrew CRIDLAND, Stuart WARD, Francis BEAUMIER, Martin DERY, Robin LAROUCHE-GAUTHIER
  • BICYCLIC PROLINE COMPOUNDS
    Publication number: 20190144428
    Abstract: The invention is concerned with the compounds of formula I: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 16, 2019
    Applicant: Genentech, Inc.
    Inventors: Vishal VERMA, Daniel SHORE, Matthew VOLGRAF, Anthony A. ESTRADA, Joseph LYSSIKATOS
  • Systems and Methods for Acquiring Consent from a Party Subject to Online Advertisement
    Publication number: 20190139087
    Abstract: A method for gaining consent to target advertising to and to collect data from a subject to online advertising includes providing, to the subject to online advertising at a computing device associated with the subject to online advertising, instructions for a consent dialogue window, the consent dialogue window served to the subject. The consent dialogue window is presented to the subject as an overlay to a website. The consent dialogue window includes a non-consent affirmation box, which, if affirmatively indicated, indicates to the consent server that the subject to online advertising does not consent to targeted advertising and collection of data, and a media declaration which accurately informs the subject that if any affirmative indication is made outside indicatable areas, which include, at least, the non-consent affirmation box, then the subject to online advertising consents to online advertisement and data collection from the vendor server and partner vendor servers.
    Type: Application
    Filed: November 6, 2018
    Publication date: May 9, 2019
    Inventors: David Dabbs, Daniel Shore, Mateen Moosa
  • Substituted sulfonamide compounds
    Patent number: 10179782
    Abstract: The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: January 15, 2019
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Elisia Villemure, Vishal Verma, Daniel Shore, Matthew Volgraf, Baihua Hu, Aijun Lu
  • Tricyclic DLK inhibitors and uses thereof
    Patent number: 10131675
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: November 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Snahel Patel, Terry Kellar, Malcolm Huestis, Daniel Shore, Michael Siu
  • SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
    Publication number: 20180282272
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Yanyan CHU, Steven DO, Anthony ESTRADA, Baihua HU, Aleksandr KOLESNIKOV, Xingyu LIN, Joseph P. LYSSIKATOS, Daniel SHORE, Vishal VERMA, Lan WANG, Guosheng WU, Po-wai YUEN
  • Biheteroaryl compounds and uses thereof
    Patent number: 10010549
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 3, 2018
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph Lyssikatos, Alan Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • BIHETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20180133219
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph Lyssikatos, Alan Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
    Publication number: 20180118680
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 3, 2018
    Applicant: Genentech, Inc.
    Inventors: Huifen Chen, Yanyan Chu, Steven Do, Anthony Estrada, Baihua Hu, Aleksandr Kolesnikov, Xingyu Lin, Joseph P. Lyssikatos, Daniel Shore, Vishal Verma, Lan Wang, Guosheng Wu, Po-wai Yuen
  • TRICYCLIC DLK INHIBITORS AND USES THEREOF
    Publication number: 20170369510
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 28, 2017
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Snahel Patel, Terry Kellar, Malcolm Huestis, Daniel Shore, Michael Siu
  • SUBSTITUTED SULFONAMIDE COMPOUNDS
    Publication number: 20160264567
    Abstract: The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.
    Type: Application
    Filed: February 12, 2016
    Publication date: September 15, 2016
    Applicant: Genentech, Inc.
    Inventors: Po-wai YUEN, Anthony ESTRADA, Huifen CHEN, Aleksandr KOLESNIKOV, Elisia VILLEMURE, Vishal VERMA, Lan WANG, Daniel SHORE, Steven DO, Matthew VOLGRAF, Baihua HU, Guosheng WU, Xingyu LIN, Aijun LU
  • SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
    Publication number: 20160221945
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: April 11, 2016
    Publication date: August 4, 2016
    Applicant: GENENTECH, INC.
    Inventors: Huifen CHEN, Yanyan CHU, Steven DO, Anthony ESTRADA, Baihua HU, Aleksandr KOLESNIKOV, Xingyu LIN, Joseph P. LYSSIKATOS, Daniel SHORE, Vishal VERMA, Lan WANG, Guosheng WU, Po-wai YUEN